Loading organizations...
Perthera develops an AI Precision Oncology Platform designed to optimize cancer treatment selection. Its core product leverages multi-omic testing results and extensive patient history, employing proprietary, patented AI technology and a vast rule set to match cancer patients with individually ranked therapy options. This intelligent engine, continuously updated with new data and real-world evidence, also accelerates therapeutic and clinical innovation.
The company was co-founded over a decade ago by Emanuel “Chip” Petricoin, a distinguished George Mason researcher and Chief Science Officer, alongside a team of oncology, bioinformatics, and scientific research experts. Their foundational insight recognized that genomic testing alone provided only a partial view of a patient’s cancer. They aimed to transform the overwhelming complexity of multi-modal molecular data and patient history into actionable intelligence for physicians, addressing the critical challenge of data interpretation.
Perthera primarily serves clinical oncologists across various care settings, providing them with advanced decision support. The platform’s data pipeline products also benefit the biopharmaceutical industry by providing insights for research and the development of new therapies. Perthera’s overarching vision is to establish precision oncology as the standard of care for all patients, continuously enhancing physician resources and driving forward therapeutic breakthroughs.
Perthera has raised $9.0M across 1 funding round.
Perthera has raised $9.0M in total across 1 funding round.
Perthera has raised $9.0M across 1 funding round. Most recently, it raised $9.0M Series A in June 2016.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jun 1, 2016 | $9M Series A | Pilot Growth Equity | — | Announced |
Perthera is an AI-driven precision oncology company whose Perthera Precision Oncology Platform synthesizes multi‑omic and clinical data to generate ranked, actionable therapy options and decision support for oncologists. [5][3]
High-Level Overview
Origin Story
Core Differentiators
Role in the Broader Tech Landscape
Quick Take & Future Outlook
Quick take: Perthera is positioned as a clinically focused therapeutic‑intelligence company that turns multi‑omic complexity into prioritized treatment actions; its near‑term value will hinge on growing adoption, maintaining RWE‑backed outcome claims, and embedding its workflows into routine oncology care to make precision oncology more actionable and scalable.[5][2]
Sources: Perthera corporate pages and press releases detailing the Perthera Report, Therapeutic Intelligence Engine, adoption metrics, POCS program and peer‑reviewed outcome claims.[2][3][4][5][6][1]
Perthera has raised $9.0M in total across 1 funding round.
Perthera's investors include Pilot Growth Equity.